Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JAN JanOne (JAN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About JanOne Stock (NASDAQ:JAN) 30 days 90 days 365 days Advanced Chart Get JanOne alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.90▼$3.4952-Week Range N/AVolume139,500 shsAverage Volume229,417 shsMarket Capitalization$20.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Read More… Receive JAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JanOne and its competitors with MarketBeat's FREE daily newsletter. Email Address JAN Stock News HeadlinesNew Dayton-based publicly traded company in the works with prominent local leaderOctober 7, 2024 | bizjournals.comJANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTSJuly 12, 2024 | prnewswire.comThe Shadow President?President Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn from the World Health Organization... exited the Paris climate accord... and begun dismantling many Federal programs... But there's ONE executive order that could go down in history as the most important of all.January 30, 2025 | Altimetry (Ad)JanOne Announces Plan to Enhance Stockholder Value Through Strategic RealignmentJuly 10, 2024 | prnewswire.com3 Fintech Stocks to Sell in July Before They Crash & BurnJuly 8, 2024 | investorplace.comJanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 SigmaJune 26, 2024 | prnewswire.comALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORMJune 25, 2024 | prnewswire.comJanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024June 13, 2024 | prnewswire.comSee More Headlines JAN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of JanOne own? Based on aggregate information from My MarketBeat watchlists, some other companies that JanOne investors own include Meta Platforms (META), NVIDIA (NVDA), Teradyne (TER), Salesforce (CRM), DraftKings (DKNG), FuboTV (FUBO) and MARA (MARA). Company Calendar Today1/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JAN CUSIPN/A CIK862861 Webwww.janone.com Phone(702) 997-5968Fax952-930-1800Employees170Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-359.71% Return on Assets-70.26% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual Sales$39.61 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / BookN/AMiscellaneous Outstanding Shares8,980,000Free Float8,707,000Market Cap$20.03 million OptionableNot Optionable Beta2.16 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:JAN) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JanOne Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share JanOne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.